BACKGROUND
lung cancer, cancer, death, cancer death
LUNG CANCER, CANCER
Clinical trials are an essential means of improving the outcomes of cancer patients. Racial minorities and females have been underrepresented in clinical trials over time. Historically, such disparities have been a problem of multiracial societies, such as the United States, but with globalization and human migration, health disparities are becoming a global concern. In February 2020, the European Parliament in its report on health inequalities in the European Union identified addressing growing health inequalities as a priority.These disparities in the representation of minorities and females in clinical trials can have significant consequences. Given these disparities, it becomes challenging to apply the findings of clinical trials to minority groups as they are not adequately represented in the trials themselves.As we enter the third decade of the 21st century, with increasing awareness and advancements in communications and global connectivity, an expectation would be that these disparities would be resolved. Given the subsequent consequences associated with such disparities, we set out to evaluate the landscape of race and sex reporting in phase III clinical trials in patients with lung cancer. We selected lung cancer for our study because, as the leading cause of cancer death in the United States, it has represented a significant proportion of phase III cancer studies (14%), and is seen across the entire spectrum of human races and sex.The purpose of our study was to determine the historical trends and current landscape of reporting and representation of females and minorities in lung cancer phase III clinical trials. We chose to study lung cancer phase III clinical trials because lung cancer is the most common cause of cancer‐related death and manifests differently depending on one's background; thus, adequate reporting and representation are essential.